This editorial refers to 'Non-endothelial cell endothelin-B receptors limit neointima formation following vascular injury' by N. S. Kirkby et al.,, this issue.
to such an environment can go walkabout. Compelling evidence indicates that SMCs have a highly plastic phenotype. Although they normally take the form of differentiated, contractile cells, changes in the environmental milieu, such as from injury, can switch the cells to a range of phenotypes that can include migrating de-differentiated cells with a synthetic and proliferative phenotype, macrophage-like, foamlike, phagocytic-like, 4 -7 and chondrocyte-like cells. 8 Many of these effects are mediated intracellularly by a host of microRNAs interacting with a multitude of cellular messenger systems. 9, 10 The dynamic nature of events within the vascular wall raises the potential for processes to malfunction. Although atherosclerosis and grafting of blood vessels pose well-established issues, lesions of the intima are increasingly coming to the fore as a result of percutaneous interventions involving balloon angioplasty and stenting to resolve stenoses. Vascular damage can result in neointima formation that involves SMC migration and hyperplasia and consequent restenosis and significant impairment of blood flow. The use of eluting stents tends to ameliorate the problem in the short term, particularly those that elute inhibitors of the mammalian target of rapamycin pathway. 3 Such eluting stents emphasize both the therapeutic potential that can arise from some understanding of neointima formation and also how much more information is still to be gleaned. The therapeutic potential of other pathways and approaches for minimizing neointima formation are thus of considerable interest. An important paracrine component of the milieu in the vascular wall is endothelin (ET-1). Originally discovered as an endotheliumderived contracting factor, it is now known to be released by a variety of cells in the vasculature including SMCs, leucocytes, macrophages, and neurons. 11 It can exert its effects via two types of receptors and multiple messenger pathways. Both ETA and ETB receptors are located on SMC; acting at these sites, ET-1 evokes contraction, while activation of ETB on the endothelial cells evokes relaxation via endothelium-derived relaxing factors, NO being the most prominent. ET-1 has other, non-contractile effects that include modifying the plasticity of the SMC phenotype, which will exacerbate neointimal lesions. 11 The promotion of inflammatory cell recruitment and neointima formation is by ET-1 derived from the endothelium, 12 acting largely via ETA receptors. 13 What about the role of ETB receptors in neointima formation and their therapeutic potential? Kirkby et al.
14 very elegantly addressed this question using a powerful, cell-type-selective, gene-modifying approach combined with selective ET-1 antagonists and optical tomography and histology to determine the lesion volume. A sophisticated approach to address the role of ETB receptors in neointima formation was essential since ETB are located on various cell types and this can give rise to opposing effects. This means that the blanket use of ETB agonists or antagonists to clarify the role of ETB may not give an indication of events at the very local level, although some studies show that ETB antagonists enhance neointima formation. 13, 15 Furthermore, mice 13 and rats 15 that genetically lacked ETB had enhanced neointima formation in injured carotid arteries. 13, 15 Kirkby et al. refined this approach by selectively deleting ETB receptors from just the endothelium and studied neointima formation in two models of vascular injury: an intraluminal guide-wire injury in femoral artery and a ligation injury in the contra-lateral femoral artery. 14 To determine the sizes of lesions, the authors went beyond the normal measurements of the surface area to determine volume using optical projection tomography, and this gave increased sensitivity. With the wire injury, an
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ETA antagonist ameliorated neointima formation, consistent with other studies. 13, 15 In contrast, ETB block dramatically enhanced neointima formation (their Fig. 3 ). Whereas ETA block was also effective in the ligation model, ETB block was without effect. 14 Given the differences in the injuries, particularly the amount of physical damage to the vessel wall in the wire model, it is perhaps not surprising that there are differences in responses. Such differences could arise from the release of various factors (cytokines, growth factors, etc.) with the wire model compared with the ligation model. A surprising result was that genetic deletion of endothelial ETB receptors had absolutely no effect on neointima formation in either injury model. Given the effectiveness of pharmacological ETB block in the wire injury model, the implication is that ETB receptors that inhibit neointima formation must be located on non-endothelial cells. This conclusion is reasonable, although it would be comforting if the authors had shown that pharmacological block of the remaining ETB receptors enhanced neointima formation. The results with the endothelium ETB deletion raise a number of questions, the most intriguing being which cells are involved. Given their abundance and involvement in hyperplasia, likely cells are those of the media, the SMC. In support of this, upregulation of ETB, as well as ETA, occurs in SMCs of human vessels following percutaneous interventions. 16 Although
Kirkby et al. recorded only a small ETB-mediated contraction in isolated non-lesioned vessels, 14 this does not exclude the possible involvement of upregulated SMC ETB in lesioned vessels 16 or non-contractile pathways. Results from SMC-specific deletion of ETB could be very informative in this regard. What about macrophages? These are also possible suspects since they migrate to sites of damage, express inducible NO synthase, and accumulate in regions of vascular injury. 16, 17 However, they tended to accumulate more towards the adventitia and to be present in only small numbers. 17 Interestingly, the latter study found increased expression of ETB in connective tissue structures, the significance of which is far from clear. Since the beneficial effects of endothelium-located ETB are likely mediated, at least partly, by the release of NO which has antiproliferative effects, how do non-endothelial ETB receptors exert their beneficial effects? Is it via NO release from other cells, such as SMCs, macrophages, or nerves? This could be readily tested with NO synthase inhibitors. Another issue common with many studies involving genetic manipulations is the question of whether there is compensatory overexpression of ETB by other cells, thus giving a perhaps somewhat less physiological picture.
Irrespective of the location of the ETB receptors, the clinical implications of the results from the Kirkby study are significant and very clear. Basal activity of ETB receptors helps minimize neointima formation. Thus, in applying ET-1 antagonists, mixed ETA/ETB receptor blockade can reduce the maximal benefits of using ETA antagonists alone. In considering the use of ETB antagonists, the answer is: let the ETB be.
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